32 research outputs found
Recommended from our members
Identification of novel epithelial ovarian cancer loci in women of African ancestry.
Women of African ancestry have lower incidence of epithelial ovarian cancer (EOC) yet worse survival compared to women of European ancestry. We conducted a genome-wide association study in African ancestry women with 755 EOC cases, including 537 high-grade serous ovarian carcinomas (HGSOC) and 1,235 controls. We identified four novel loci with suggestive evidence of association with EOC (p < 1 × 10-6 ), including rs4525119 (intronic to AKR1C3), rs7643459 (intronic to LOC101927394), rs4286604 (12 kb 3' of UGT2A2) and rs142091544 (5 kb 5' of WWC1). For HGSOC, we identified six loci with suggestive evidence of association including rs37792 (132 kb 5' of follistatin [FST]), rs57403204 (81 kb 3' of MAGEC1), rs79079890 (LOC105376360 intronic), rs66459581 (5 kb 5' of PRPSAP1), rs116046250 (GABRG3 intronic) and rs192876988 (32 kb 3' of GK2). Among the identified variants, two are near genes known to regulate hormones and diseases of the ovary (AKR1C3 and FST), and two are linked to cancer (AKR1C3 and MAGEC1). In follow-up studies of the 10 identified variants, the GK2 region SNP, rs192876988, showed an inverse association with EOC in European ancestry women (p = 0.002), increased risk of ER positive breast cancer in African ancestry women (p = 0.027) and decreased expression of GK2 in HGSOC tissue from African ancestry women (p = 0.004). A European ancestry-derived polygenic risk score showed positive associations with EOC and HGSOC in women of African ancestry suggesting shared genetic architecture. Our investigation presents evidence of variants for EOC shared among European and African ancestry women and identifies novel EOC risk loci in women of African ancestry
Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer
Background Genome-wide association studies (GWAS) identify associations of individual single-nucleotide polymorphisms (SNPs) with cancer risk but usually only explain a fraction of the inherited variability. Pathway analysis of genetic variants is a powerful tool to identify networks of susceptibility genes. Methods We conducted a large agnostic pathway-based meta-analysis of GWAS data using the summary-based adaptive rank truncated product method to identify gene sets and pathways associated with pancreatic ductal adenocarcinoma (PDAC) in 9040 cases and 12 496 controls. We performed expression quantitative trait loci (eQTL) analysis and functional annotation of the top SNPs in genes contributing to the top associated pathways and gene sets. All statistical tests were two-sided. Results We identified 14 pathways and gene sets associated with PDAC at a false discovery rate of less than 0.05. After Bonferroni correction (P Conclusion Our agnostic pathway and gene set analysis integrated with functional annotation and eQTL analysis provides insight into genes and pathways that may be biologically relevant for risk of PDAC, including those not previously identified.Peer reviewe
Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer.
In 2020, 146,063 deaths due to pancreatic cancer are estimated to occur in Europe and the United States combined. To identify common susceptibility alleles, we performed the largest pancreatic cancer GWAS to date, including 9040 patients and 12,496 controls of European ancestry from the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4). Here, we find significant evidence of a novel association at rs78417682 (7p12/TNS3, P = 4.35 × 10-8). Replication of 10 promising signals in up to 2737 patients and 4752 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium yields new genome-wide significant loci: rs13303010 at 1p36.33 (NOC2L, P = 8.36 × 10-14), rs2941471 at 8q21.11 (HNF4G, P = 6.60 × 10-10), rs4795218 at 17q12 (HNF1B, P = 1.32 × 10-8), and rs1517037 at 18q21.32 (GRP, P = 3.28 × 10-8). rs78417682 is not statistically significantly associated with pancreatic cancer in PANDoRA. Expression quantitative trait locus analysis in three independent pancreatic data sets provides molecular support of NOC2L as a pancreatic cancer susceptibility gene
Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.
An association between genetic variants in the vitamin D receptor (VDR) gene and epithelial ovarian cancer (EOC) was previously reported in women of African ancestry (AA). We sought to examine associations between genetic variants in VDR and additional genes from vitamin D biosynthesis and pathway targets (EGFR, UGT1A, UGT2A1/2, UGT2B, CYP3A4/5, CYP2R1, CYP27B1, CYP24A1, CYP11A1, and GC). Genotyping was performed using the custom-designed 533,631 SNP Illumina OncoArray with imputation to the 1,000 Genomes Phase 3 v5 reference set in 755 EOC cases, including 537 high-grade serous (HGSOC), and 1,235 controls. All subjects are of African ancestry (AA). Logistic regression was performed to estimate odds ratios (OR) and 95% confidence intervals (CI). We further evaluated statistical significance of selected SNPs using the Bayesian False Discovery Probability (BFDP). A significant association with EOC was identified in the UGT2A1/2 region for the SNP rs10017134 (per allele OR = 1.4, 95% CI = 1.2-1.7, P = 1.2 × 10-6 , BFDP = 0.02); and an association with HGSOC was identified in the EGFR region for the SNP rs114972508 (per allele OR = 2.3, 95% CI = 1.6-3.4, P = 1.6 × 10-5 , BFDP = 0.29) and in the UGT2A1/2 region again for rs1017134 (per allele OR = 1.4, 95% CI = 1.2-1.7, P = 2.3 × 10-5 , BFDP = 0.23). Genetic variants in the EGFR and UGT2A1/2 may increase susceptibility of EOC in AA women. Future studies to validate these findings are warranted. Alterations in EGFR and UGT2A1/2 could perturb enzyme efficacy, proliferation in ovaries, impact and mark susceptibility to EOC.Includes NIHR and CRUK
Influence of UGT2B10 Genotype on Urinary Excretion of 4‑(Methylnitrosamino)-1-(3-pyridyl)-1-butanol-<i>N-</i>glucuronide by African American Smokers
At
similar smoking levels, African American’s lung cancer
risk is as much as twice that of whites. We hypothesized that racial/ethnic
differences in UDP-glucuronosyltransferase (UGT)-catalyzed glucuronidation
of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a detoxication
pathway for the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
(NNK) may contribute to this variable risk. UGT2B10 catalyzes NNAL-<i>N</i>-glucuronidation, and a UGT2B10 splice variant is common
among African Americans. Smokers from two independent studies were
genotyped for this variant (rs116294140) and an Asp67Tyr variant (rs61750900),
and urinary NNAL and NNAL-glucuronide concentrations were quantified.
In the first, no significant differences in NNAL-<i>N</i>-glucuronidation between African Americans (<i>n</i> =
257) and whites (<i>n</i> = 354) or between homozygous carriers
of UGT2B10 variants (genetic score 2) and noncarriers (score 0) were
detected. However, total NNAL glucuronidation by score 2 compared
to score 0 smokers was lower (68.9 vs 71.2%, <i>p</i> <
0.0001). For NNAL-<i>N</i>-glucuronide to be more precisely
quantified in a second study, a sensitive high-resolution LC-MS/MS-based
method, which separated NNAL, NNAL-<i>O</i>-glucuronide,
and NNAL-<i>N</i>-glucuronide prior to analysis, was developed.
In this study, the excretion of total NNAL (free plus glucuronides)
by African American (<i>n</i> = 52) and white (<i>n</i> = 54) smokers was not different; however, total NNAL glucuronidation
by African Americans (64.0%) was slightly less than by whites (68.3%, <i>p</i> = 0.05). The mean NNAL-<i>N</i>-glucuronidation
by African Americans was much lower than for whites (14 vs 24.9%, <i>p</i> < 0.00001), but the NNAL-<i>O</i>-glucuronidation
was greater (50.0 vs 43.3%, <i>p</i> = 0.013). <i>UGT2B10</i> genotype influenced NNAL-<i>N</i>-glucuronidation; the
geometric mean percentage <i>N</i>-glucuronidation was 22.5%
for smokers with genetic score 0 (<i>n</i> = 57) and 11.2%
for score 2 (<i>n</i> = 11). In summary, the high prevalence
of a <i>UGT2B10</i> splice variant among African Americans
results in lower NNAL-<i>N</i>-glucuronidation but only
a small decrease in total NNAL glucuronidation. Therefore, despite
the significant contribution of UGT2B10 to NNAL-<i>N-</i>glucuronidation, the <i>UGT2B10</i> genotype does not play
a large role in NNAL detoxication. Any decrease in <i>N</i>-glucuronidation was accompanied by a parallel increase in <i>O</i>-glucuronidation
Germline MutY Human Homologue Mutations and Colorectal Cancer:A Multisite Case-Control Study
BACKGROUND & AIMS: The MutY human homologue (MYH) gene is a member of the base-excision repair pathway involved in the repair of oxidative DNA damage. The objective of this study was to determine colorectal cancer (CRC) risk associated with mutations in the MYH gene. METHODS: A total of 3811 CRC cases and 2802 controls collected from a multisite CRC registry were screened for 9 germline MYH mutations; subjects with any mutation underwent screening of the entire MYH gene. Logistic regression was used to estimate age- and sex-adjusted odds ratios (AOR). Clinicopathologic and epidemiologic data were reviewed to describe the phenotype associated with MYH mutation status and assess for potential confounding and effect modification. RESULTS: Twenty-seven cases and 1 control subject carried homozygous or compound heterozygous MYH mutations (AOR, 18.1; 95% confidence interval, 2.5–132.7). CRC cases with homozygous/compound heterozygous mutations were younger at diagnosis (P = .01), had a higher proportion of right-sided (P = .01), synchronous cancers (P < .01), and personal history of adenomatous polyps (P = .003). Heterozygous MYH mutations were identified in 87 CRC cases and 43 controls; carriers were at increased risk of CRC (AOR, 1.48; 95% confidence interval, 1.02–2.16). There was a higher prevalence of low-frequency microsatellite instability (MSI) in tumors from heterozygous and homozygous/compound heterozygous MYH mutation carriers (P = .02); MSI status modified the CRC risk associated with heterozygous MYH mutations (P interaction < .001). CONCLUSIONS: Homozygous/compound heterozygous MYH mutations account for less than 1% of CRC cases. Heterozygous carriers are at increased risk of CRC. Further studies are needed to understand the possible interaction between the base excision repair and low-frequency MSI pathways
Comparison of the clinical prediction model PREMM1,2,6 and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer
Background Lynch syndrome is caused by germline
mismatch repair (MMR) gene mutations. The
PREMM1,2,6 model predicts the likelihood of a MMR
gene mutation based on personal and family cancer
history.
Objective To compare strategies using PREMM1,2,6 and
tumour testing (microsatellite instability (MSI) and/or
immunohistochemistry (IHC) staining) to identify
mutation carriers.
Design Data from population-based or clinic-based
patients with colorectal cancers enrolled through the
Colon Cancer Family Registry were analysed. Evaluation
included MSI, IHC and germline mutation analysis for
MLH1, MSH2, MSH6 and PMS2. Personal and family
cancer histories were used to calculate PREMM1,2,6
predictions. Discriminative ability to identify carriers from
non-carriers using the area under the receiver operating
characteristic curve (AUC) was assessed. Predictions
were based on logistic regression models for (1) cancer
assessment using PREMM1,2,6, (2) MSI, (3) IHC for
loss of any MMR protein expression, (4) MSI+IHC,
(5) PREMM1,2,6+MSI, (6) PREMM1,2,6+IHC,
(7) PREMM1,2,6+IHC+MSI.
Results Among 1651 subjects, 239 (14%) had
mutations (90 MLH1, 125 MSH2, 24 MSH6).
PREMM1,2,6 discriminated well with AUC 0.90 (95% CI
0.88 to 0.92). MSI alone, IHC alone, or MSI+IHC each
had lower AUCs: 0.77, 0.82 and 0.82, respectively. The
added value of IHC+PREMM1,2,6 was slightly greater
than PREMM1,2,6+MSI (AUC 0.94 vs 0.93). Adding MSI
to PREMM1,2,6+IHC did not improve discrimination.
Conclusion PREMM1,2,6 and IHC showed excellent
performance in distinguishing mutation carriers from noncarriers and performed best when combined. MSI may
have a greater role in distinguishing Lynch syndrome
from other familial colorectal cancer subtypes among
cases with high PREMM1,2,6 scores where genetic
evaluation does not disclose a MMR mutation